Reimbursement Briefs: 340B, Exchange Plan Cost-Sharing, Part D Dual Eligibles
HRSA’s Office of Pharmacy Affairs adds a new branch to oversee compliance in the 340B drug discount program; a PhRMA-funded study finds high coinsurance for drugs used by enrollees in many state exchange plans; OIG says Part D plans are covering a high percentage of drugs used by Medicare/Medicaid dual eligibles.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.